Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to allegations of violations of federal securities laws, particularly regarding misleading statements and guidance related to the company's financial performance [2][4]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses in agilon health between February 26, 2025, and August 4, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against agilon health, with a deadline of March 2, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that agilon health and its executives made false statements and failed to disclose significant industry challenges, leading to misleading information about the company's business and financial outlook [4]. Group 2: Financial Impact and Stock Performance - On August 4, 2025, agilon health announced the suspension of its full-year 2025 financial guidance, citing more severe industry headwinds than previously anticipated [5]. - Following this announcement, agilon health's stock experienced a significant decline of 51.5% on August 5, 2025 [5]. Group 3: Firm Background and Encouragement for Whistleblowers - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding agilon health's conduct [7].

Agilon Health Deadline: AGL Investors with Losses in Excess of $100K Have Opportunity to Lead agilon health, inc. Securities Fraud Lawsuit First Filed by the Rosen Law Firm [Accessibility Statement] Skip NavigationNEW YORK, Feb. 20, 2026 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of agilon health, inc. (NYSE: AGL) between February 26, 2025 and August 4, 2025, both dates inclusive (the "Class Period"), of the important March 2, 2026 lead plaintiff ...

Core Viewpoint - A class action lawsuit has been filed against agilon health, inc. for allegedly making false statements and failing to disclose critical information regarding its financial guidance and the impact of strategic actions taken by the company [4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased agilon securities between February 26, 2025, and August 4, 2025, alleging that the company issued misleading guidance for 2025 despite being aware of significant industry challenges [4]. - The lawsuit claims that agilon overstated the positive financial impact from its strategic actions aimed at reducing risk [4]. Group 2: Company Events - On August 4, 2025, agilon announced the resignation of its President and CEO, Steven Sell, which was classified as a termination without cause [5]. - The same day, agilon reported its second-quarter results and acknowledged that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [5]. - Following these announcements, agilon's stock price fell by $0.94, or approximately 51.6%, from $1.82 to $0.88 per share [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - The Class Period for the agilon securities is from February 26, 2025, to August 4, 2025 [1] - Investors who purchased agilon securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 2, 2026 [3] Group 2: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding agilon's financial guidance for 2025, which they knew was unattainable due to industry challenges [5] - It is claimed that defendants overstated the positive financial impact from strategic actions taken by agilon to mitigate risks [5] - As a result, the statements made about agilon's business operations and prospects were materially false and misleading, leading to investor damages when the truth was revealed [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and success in this area [4]

Core Viewpoint - A class action securities lawsuit has been filed against agilon health, inc. (AGL) for alleged securities fraud affecting investors between February 26, 2025, and August 4, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements and concealed information regarding the company's 2025 guidance, which was deemed unachievable due to known industry challenges [1] - It is alleged that defendants overstated the financial benefits from strategic actions taken by agilon to mitigate risks, leading to materially false and misleading statements about the company's business and prospects [1] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until March 2, 2026, to request appointment as lead plaintiff, with no costs or obligations to participate in the lawsuit [1] - Levi & Korsinsky, LLP, the law firm handling the case, has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [1]

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Agilon (AGL) To Contact Him Directly To Discuss Their Options If you purchased or acquired Agilon securities between February 26, 2025 and August 4, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- What’s Happening? Brag ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - The Class Period for the agilon securities is from February 26, 2025, to August 4, 2025 [1] - Investors who purchased agilon securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 2, 2026 [3] Group 2: Case Allegations - The lawsuit alleges that defendants made false or misleading statements and failed to disclose critical information, including unrealistic guidance for 2025 and overstated financial impacts from strategic actions [5] - The claims suggest that the defendants were aware of material industry headwinds that would prevent achieving the stated guidance [5] - As a result of these misleading statements, investors suffered damages when the true information became public [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]

SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired agilon health, inc. (NYSE: AGL) securities between February 26, 2025 and August 4, 2025. Agilon describes itself as the "trusted partner empowering physicians to transform health care in our communities." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the allegations? Rob ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities between February 26, 2025, and August 4, 2025, about the upcoming lead plaintiff deadline for a class action lawsuit set for March 2, 2026 [1]. Group 1: Class Action Details - Investors who bought agilon securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by March 2, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing their capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made false or misleading statements and failed to disclose critical information regarding agilon's financial guidance and strategic actions, which were not achievable due to known industry challenges [5]. - It is claimed that these misleading statements resulted in investor damages when the true situation was revealed [5].

Core Viewpoint - Agilon Health, Inc. is facing a securities fraud lawsuit initiated by the Rosen Law Firm, with a lead plaintiff deadline set for March 2, 2026, for investors who purchased securities between February 26, 2025, and August 4, 2025 [1] Group 1: Lawsuit Details - The lawsuit alleges that Agilon's management made false and misleading statements regarding the company's financial guidance for 2025, which they knew was unattainable due to industry challenges [1] - It is claimed that Agilon overstated the positive financial impact from strategic actions taken to mitigate risks, leading to materially false representations about the company's business and prospects [1] - Investors are encouraged to join the class action without incurring out-of-pocket fees, as the Rosen Law Firm operates on a contingency fee basis [1] Group 2: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [1] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [1] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise in handling such cases [1]